MedPath

Effect of Cilostazol compared with Clopidogrel about prevention of myocardial injury after elective percutaneous coronary intervention :Prospective,Randomized,Open,Blinded-Endpoint trial

Not Applicable
Conditions
ischemic heart disease
Registration Number
JPRN-UMIN000002351
Lead Sponsor
Department of Cardiology, Nagoya University Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

(1)Patients with unstable angina (2)Patients who use drug-eluting stents (DES) (3)Patients with a medical history of acute myocardial infarction within three months (4)Patients whose levels of CK and CK-MB,troponin-I are above upper limits of normal at the time of consent acquisition (5)Patients taking an anticoagulant (warfarin) (6)Patients who have a medical history of hypersensitivity to cilostazol, aspirin, and/or clopidogrel (7)Patients with thrombocytopenia (8)Patients with hepatic dysfunction (AST (GOT) or ALT(GPT) > 100 IU/L within three months) (9)Patients with renal dysfunction (serum creatinine >2.0mg/dl within three months) (10)Patients with congestive heart failure (11)Patients who are pregnant (12)Patients with bleeding

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath